Zealand Pharma Targets Next-Gen Weight Loss Drug with Dapiglutide

Oct 11, 2024

Danish biotechnology company Zealand Pharma is aiming to develop the "next generation" of weight loss drugs, challenging the dominance of major players Novo Nordisk and Eli Lilly in the weight management market. Early trials show that Zealand Pharma's experimental injectable offers higher quality weight loss, with reduced muscle loss and fewer side effects compared to traditional GLP-1 receptor agonist treatments.

CEO Adam Steensberg stated the company is seeking a global pharmaceutical partner to advance their efforts. He emphasized that their focus is on developing new molecular drugs that are not based on GLP-1 receptor agonists, targeting the needs of the 2030s.

Last month, Zealand Pharma announced positive results from the Phase 1b trial of their GLP-1/GLP-2 receptor dual agonist, Dapiglutide. This positions Zealand Pharma to directly compete with existing market leaders Novo Nordisk and Eli Lilly, whose GLP-1s, Wegovy and Zepbound, are popular weight loss treatments.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.